Ketamine or Placebo in Patients With Major Depression and Advanced Cancer

  • STATUS
    Recruiting
  • participants needed
    24
  • sponsor
    Instituto Nacional de Cancerologia de Mexico
Send
Updated on 16 February 2024
See if I qualify
depressive disorder
psychiatric disorder
suicidal
cancer
anhedonia
ketamine
depression
sleep disorder
fatigue
cancer diagnosis
major depressive disorder
advanced cancer

Summary

Major depression (MD) is a psychiatric disorder characterized by a persistent feeling of sadness, anhedonia or a decreased perception of pleasurable experiences, as well as appetite alterations and weight variations, sleep disorders, altered psychomotor skills, fatigue, guilt, decreased self-worth, suicidal thoughts and difficulty concentrating in a task (1).

MD is a frequent complication in patients who are diagnosed with advanced cancer.

Details
Condition Major depression, Endogenous depression, Advanced Cancer
Age 18years - 65years
Treatment Placebo, Ketamine
Clinical Study IdentifierNCT04471818
SponsorInstituto Nacional de Cancerologia de Mexico
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Age: 18 to 65 years of age
Sex: Male or female
Major depressive disorder (MDD) diagnosis as per Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
Palliative stage cancer diagnosis (advanced-disease stage)
Who can read and write in spanish
Eastern Cooperative Oncology Group (ECOG) 0-2
Karnofsky 50
Palliative prognostic index A
Not currently undergoing systemic oncologic treatment
Patients who agree to participate in the study by signing an informed consent

Exclusion Criteria

Comorbidities including other psychiatric diseases (additional to MDD, generalized anxiety or panic disorder)
Magnetic resonance or computerized tomography with major structural alterations
Pregnant or breastfeeding women
Patients with hypersensitivity to ketamine
Cardiac insufficiency
Patients with a history of psychosis
Patients with first-degree relatives with a history of psychosis
Patients with uncontrolled glaucoma
Current neurological illness
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

depressive disorder
psychiatric disorder
suicidal
cancer
anhedonia
ketamine
depression
sleep disorder
fatigue
cancer diagnosis
major depressive disorder
advanced cancer

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.